Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry

Blank N, Schmalzing M, Moinzadeh P, Oberste M, Siegert E, Mueller-Ladner U, Riemekasten G, Guenther C, Koetter I, Zeidler G, Pfeiffer C, Juche A, Jandova I, Ehrchen J, Susok L, Schmeiser T, Sunderkoetter C, Distler J, Worm M, Kreuter A, Keysser G, Lorenz HM, Krieg T, Hunzelmann N, Henes J (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 24

Journal Issue: 1

DOI: 10.1186/s13075-022-02948-x

Abstract

Background Current recommendations on the management of systemic sclerosis (SSc) suggest that autologous hematopoietic stem cell therapy (HSCT) can be a rescue therapy for patients with rapidly progressive SSc. Objectives To assess the safety and efficacy of HSCT for patients with SSc and to compare these with non-HSCT patients in a control cohort with adjusted risk factors. Methods A retrospective analysis of data from the multicentric German network for systemic scleroderma (DNSS) with 5000 patients with SSc. Control groups consisted of all patients with diffuse cutaneous (dc)-SSc (group A) and an adjusted high-risk cohort of male patients with Scl70-positive dc-SSc (group B). Results Eighty SSc patients received an HSCT 4.1 +/- 4.8 years after SSc diagnosis. Among them, 86.3% had dc-SSc, 43.5% were males, and 71.3% were positive for Scl70 antibodies. The control group A (n=1513) showed a significant underrepresentation of these risk factors for mortality. When the survival of the control group B (n=240) was compared with the HSCT group, a lower mortality of the latter was observed instead. Within 5 years after HSCT, we observed an improvement of the mRSS from 17.6 +/- 11.5 to 11.0 +/- 8.5 (p=0.001) and a stabilization of the DLCO. We did not see differences in transplant-related mortality between patients who received HSCT within 3 years after SSc diagnosis or later. Conclusion Our analysis of real-life data show that the distribution of risk factors for mortality is critical when HSCT cohorts are compared with non-HSCT control groups.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Würzburg Germany (DE) Universitätsklinikum Köln Germany (DE) Universität zu Köln Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Justus-Liebig-Universität Gießen Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Immanuel Krankenhaus Berlin Germany (DE) Universitätsklinikum Freiburg Germany (DE) Universitätsklinikum Münster Germany (DE) Ruhr-Universität Bochum (RUB) Germany (DE) Krankenhaus St. Josef Germany (DE) Universitätsklinikum Halle (Saale) Germany (DE) Universität Witten/Herdecke Germany (DE) Universitätsklinikum Tübingen Germany (DE)

How to cite

APA:

Blank, N., Schmalzing, M., Moinzadeh, P., Oberste, M., Siegert, E., Mueller-Ladner, U.,... Henes, J. (2022). Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry. Arthritis Research & Therapy, 24(1). https://doi.org/10.1186/s13075-022-02948-x

MLA:

Blank, Norbert, et al. "Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry." Arthritis Research & Therapy 24.1 (2022).

BibTeX: Download